MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
ROCKVILLE, MD, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will present at the H.C. Wainwright 28th Annual Gl…
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


